Latest immunotherapy Stories

Series of five webinars will discuss cutting-edge research and breakthroughs in immune treatments for cancers and ways to get involved in immunotherapy NEW YORK, May 22, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, is holding a series of five webinars in June to talk about breakthroughs in cancer immunotherapy research and treatments as part of Cancer Immunotherapy...

BETHESDA, Md., May 20, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the OTC Markets' OTCQB marketplace under the ticker symbol "TNIB" commencing May 17, 2013. Investors will be able to view the real-time Level II stock quotes for TNIB at http://www.otcmarkets.com/stock/TNIB/quote. Noreen...

BETHESDA, Md., May 16, 2013 /PRNewswire/ -- TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows: Dear Shareholders, The board of directors of TNI BioTech, Inc. is very pleased to provide an update on the progress made over the last year....

LOS ANGELES, May 15, 2013 /PRNewswire/ -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series A Preferred Stock. In addition to the $20 million in new funds, Kite converted $15 million in outstanding promissory notes into shares of Series A Preferred Stock. Joined by a new investor, Alta Partners, all existing...

ROUND ROCK, Texas, May 15, 2013 /PRNewswire/ -- In the latest effort to educate and enable the allergic patient to take control of their disease, ALK, a leading company focusing on allergy treatment, and the Asthma and Allergy Foundation of America (AAFA) have partnered to create a unique online resource for patients. The website, launching during May, National Asthma and Allergy Awareness month, will be the first dedicated to the importance of allergy immunotherapy. The goal is to...

The Cancer Research Institute (CRI) declares June “Cancer Immunotherapy Awareness Month” to increase awareness of cancer immunotherapy, a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. The month will feature educational webinars offered free to the public from top experts in cancer immunotherapy, and a Wear White for a Cure Day on June 7. New York, NY (PRWEB) May 08,...

Amplification of RCC RNA Evaluated Using Newly Developed Techniques DURHAM, N.C., May 8, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company's improved RNA...

redOrbit Staff & Wire Reports - Your Universe Online A once-a-day pill containing high levels of a specific ragweed pollen protein has proven effective in relieving the symptoms experienced by those allergic to the flowering plants, claims new research published Tuesday in the Journal of Allergy and Clinical Immunology. Tests conducted by an international team of experts discovered that treatment with the drug, which contained protein Ambrosia artemisiifolia major allergen 1, helped...

Allergy & Asthma Network Mothers of Asthmatics Asks Congress to Protect Patients From Fraud and Sub-Standard Allergy Care WASHINGTON, May 6, 2013 /PRNewswire-USNewswire/ -- Add-on allergy testing and immunotherapy schemes are popping up in primary care practices across the country - exposing patients and families to less-than-professional diagnosis and therapy and raising a potential for fraud. More than 2,000 primary care offices have entered into agreements with third-party...

Board-certified family medicine physician Dr. Alexandra C. Caracitas discusses the differences between allergies and colds. Perth Amboy, NJ (PRWEB) May 03, 2013 One of the most common diagnoses seen in primary care, with the start of spring, is seasonal allergies. The symptoms from seasonal allergies are often confused with those of the “common cold.” As a result, patients are often reluctant to come to their primary care physicians initially hoping that their symptoms will resolve on...